ChartMill assigns a Buy % Consensus number of 86% to TRVI. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-20 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-11-14 | Clear Street | Maintains | Buy -> Buy |
| 2025-11-14 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-14 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-11-14 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-08-21 | Morgan Stanley | Initiate | Overweight |
| 2025-08-08 | Needham | Maintains | Buy -> Buy |
| 2025-08-08 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2025-07-01 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-06-02 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-05-28 | HC Wainwright & Co. | Initiate | Buy |
| 2025-05-20 | Needham | Reiterate | Buy -> Buy |
| 2025-04-08 | Needham | Reiterate | Buy -> Buy |
| 2025-03-19 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-19 | Needham | Maintains | Buy -> Buy |
| 2025-03-19 | B. Riley Securities | Reiterate | Buy -> Buy |
| 2025-03-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-11 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-03-10 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-10 | Needham | Maintains | Buy -> Buy |
| 2025-03-10 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2025-03-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-07 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-02-24 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-08 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-12-16 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-12-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-12 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-12-12 | Needham | Reiterate | Buy -> Buy |
| 2024-12-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
18 analysts have analysed TRVI and the average price target is 20.15 USD. This implies a price increase of 49.55% is expected in the next year compared to the current price of 13.47.
The consensus rating for TREVI THERAPEUTICS INC (TRVI) is 85.5556 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering TREVI THERAPEUTICS INC (TRVI) is 18.